Doyle Brendan J, Ting Henry H, Bell Malcolm R, Lennon Ryan J, Mathew Verghese, Singh Mandeep, Holmes David R, Rihal Charanjit S
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
JACC Cardiovasc Interv. 2008 Apr;1(2):202-9. doi: 10.1016/j.jcin.2007.12.006.
The purpose of this study was to evaluate secular trends and factors associated with major femoral bleeding after percutaneous coronary intervention (PCI) in routine clinical practice during the past decade and to assess the impact of these complications on outcomes including mortality.
Significant changes in patient demographic data, adjunctive pharmacotherapy, and access site management have occurred during the coronary stent era. Trends in major vascular complications after PCI during this time have not been well characterized.
Consecutive patients who underwent transfemoral PCI from 1994 to 2005 at the Mayo Clinic (n = 17,901) were studied. Patients were divided into 3 groups: Group 1 (1994 to 1995, n = 2,441); Group 2 (1996 to 1999, n = 6,207); and Group 3 (2000 to 2005, n = 9,253).
The incidence of major femoral bleeding complications decreased (from 8.4% to 5.3% to 3.5%; p < 0.001). Reductions in sheath size, intensity and duration of anticoagulation with heparin, and procedure time were observed (p < 0.001), and multivariate analysis confirmed each as an independent predictor of complications (p < 0.001). Adverse outcomes of major femoral bleeding included prolonged hospital stay (mean 4.5 vs. 2.7 days; p < 0.0001) and increased requirement for blood transfusion (39% vs. 4.7%; p < 0.0001). Major femoral bleeding and blood transfusion were both associated with decreased long-term survival, driven by a significant increase in 30-day mortality (p < 0.001 for both).
We noted a marked decline in the incidence of major femoral bleeding after PCI over the past decade. Mortality associated with these bleeding complications and with blood transfusion remains a significant issue.
本研究旨在评估过去十年常规临床实践中经皮冠状动脉介入治疗(PCI)后股动脉大出血的长期趋势及相关因素,并评估这些并发症对包括死亡率在内的预后的影响。
在冠状动脉支架时代,患者人口统计学数据、辅助药物治疗及穿刺部位管理发生了显著变化。此时PCI后主要血管并发症的趋势尚未得到充分描述。
对1994年至2005年在梅奥诊所接受经股动脉PCI的连续患者(n = 17,901)进行研究。患者分为3组:第1组(1994年至1995年,n = 2,441);第2组(1996年至1999年,n = 6,207);第3组(2000年至2005年,n = 9,253)。
股动脉大出血并发症的发生率下降(从8.4%降至5.3%再降至3.5%;p < 0.001)。观察到鞘管尺寸减小以及肝素抗凝强度和持续时间及手术时间缩短(p < 0.001),多因素分析证实每一项均为并发症的独立预测因素(p <